{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:20:48Z","timestamp":1789852848722,"version":"4.0.1"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/4\/1-2\/2019-NCD-II"],"award-info":[{"award-number":["5\/4\/1-2\/2019-NCD-II"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10067-021-05743-2","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T12:05:23Z","timestamp":1620043523000},"page":"4391-4416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis\u2014a systematic review and meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-7396","authenticated-orcid":false,"given":"Durga Prasanna","family":"Misra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1658-8155","authenticated-orcid":false,"given":"Upendra","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7645-5883","authenticated-orcid":false,"given":"Pallavi","family":"Patro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4508-1233","authenticated-orcid":false,"given":"Vikas","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0813-1243","authenticated-orcid":false,"given":"Aman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"key":"5743_CR1","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s10067-020-05357-0","volume":"39","author":"DP Misra","year":"2020","unstructured":"Misra DP, Agarwal V (2020) The perennial search for alternatives to corticosteroids in rheumatology: is there light at the end of the tunnel? Clin Rheumatol 39:2845\u20132848. https:\/\/doi.org\/10.1007\/s10067-020-05357-0","journal-title":"Clin Rheumatol"},{"issue":"Suppl 1","key":"5743_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/1756-185x.13285","volume":"22","author":"DP Misra","year":"2019","unstructured":"Misra DP, Wakhlu A, Agarwal V, Danda D (2019) Recent advances in the management of Takayasu arteritis. Int J Rheum Dis 22(Suppl 1):60\u201368. https:\/\/doi.org\/10.1111\/1756-185x.13285","journal-title":"Int J Rheum Dis"},{"key":"5743_CR3","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.injr.2015.08.006","volume":"10","author":"DP Misra","year":"2015","unstructured":"Misra DP, Misra R (2015) Assessment of disease activity in Takayasu's arteritis. Indian J Rheumatol 10:S43\u2013S47. https:\/\/doi.org\/10.1016\/j.injr.2015.08.006","journal-title":"Indian J Rheumatol"},{"key":"5743_CR4","unstructured":"OCEBM Levels of Evidence Working Group*. \"The Oxford 2011 Levels of Evidence\". Oxford Centre for Evidence-Based Medicine. http:\/\/www.cebm.net\/index.aspx?o=5653 [Accessed on 01 March 2021]"},{"key":"5743_CR5","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s10067-019-04590-6","volume":"38","author":"GA Kelley","year":"2019","unstructured":"Kelley GA, Kelley KS (2019) Systematic reviews and meta-analysis in rheumatology: a gentle introduction for clinicians. Clin Rheumatol 38:2029\u20132038. https:\/\/doi.org\/10.1007\/s10067-019-04590-6","journal-title":"Clin Rheumatol"},{"key":"5743_CR6","doi-asserted-by":"publisher","unstructured":"Pacheco RL, Latorraca COC, de Souza AWS, Pachito DV, Riera R (2017) Clinical interventions for Takayasu arteritis: a systematic review. Int J Clin Pract 71. https:\/\/doi.org\/10.1111\/ijcp.12993","DOI":"10.1111\/ijcp.12993"},{"key":"5743_CR7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.autrev.2018.01.019","volume":"17","author":"L Barra","year":"2018","unstructured":"Barra L, Yang G, Pagnoux C (2018) Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: a systematic review and meta-analysis. Autoimmun Rev 17:683\u2013693. https:\/\/doi.org\/10.1016\/j.autrev.2018.01.019","journal-title":"Autoimmun Rev"},{"key":"5743_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.autrev.2016.12.009","volume":"16","author":"DP Misra","year":"2017","unstructured":"Misra DP, Sharma A, Kadhiravan T, Negi VS (2017) A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis. Autoimmun Rev 16:179\u2013191. https:\/\/doi.org\/10.1016\/j.autrev.2016.12.009","journal-title":"Autoimmun Rev"},{"key":"5743_CR9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.autrev.2016.02.012","volume":"15","author":"Y Ferfar","year":"2016","unstructured":"Ferfar Y, Mirault T, Desbois AC, Comarmond C, Messas E, Savey L, Domont F, Cacoub P, Saadoun D (2016) Biotherapies in large vessel vasculitis. Autoimmun Rev 15:544\u2013551. https:\/\/doi.org\/10.1016\/j.autrev.2016.02.012","journal-title":"Autoimmun Rev"},{"key":"5743_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/acr2.11186","volume":"3","author":"AB Dua","year":"2021","unstructured":"Dua AB, Kalot MA, Husainat NM, Byram K, Springer JM, James KE, Chang Lin Y, Turgunbaev M, Villa-Forte A, Abril A, Langford C, Maz M, Chung SA, Mustafa RA (2021) Takayasu arteritis: a systematic review and meta-analysis of test accuracy and benefits and harms of common treatments. ACR Open Rheumatol 3:80\u201390. https:\/\/doi.org\/10.1002\/acr2.11186","journal-title":"ACR Open Rheumatol"},{"key":"5743_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4103\/injr.injr_34_21","volume":"16","author":"U Rathore","year":"2021","unstructured":"Rathore U, Patro P, Agarwal V, Sharma A, Misra DP (2021) Disease modifying antirheumatic drugs for the management of Takayasu arteritis\u2014protocol for a systematic review. Indian J Rheumatol 16:79\u201382","journal-title":"Indian J Rheumatol"},{"key":"5743_CR12","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2019) Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons.","DOI":"10.1002\/9781119536604"},{"key":"5743_CR13","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097\u2013e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"5743_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","volume":"10","author":"ML Rethlefsen","year":"2021","unstructured":"Rethlefsen ML, Kirtley S, Waffenschmidt S et al (2021) PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev 10:39. https:\/\/doi.org\/10.1186\/s13643-020-01542-z","journal-title":"Syst Rev"},{"key":"5743_CR15","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/art.1780330811","volume":"33","author":"WP Arend","year":"1990","unstructured":"Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, Masi AT, McShane DJ, Mills JA, Stevens MB, Wallace SL, Zvaifler NJ (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129\u20131134. https:\/\/doi.org\/10.1002\/art.1780330811","journal-title":"Arthritis Rheum"},{"key":"5743_CR16","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/0735-1097(88)90462-7","volume":"12","author":"K Ishikawa","year":"1988","unstructured":"Ishikawa K (1988) Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu's arteriopathy. J Am Coll Cardiol 12:964\u2013972. https:\/\/doi.org\/10.1016\/0735-1097(88)90462-7","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"5743_CR17","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1016\/S0167-5273(96)88783-3","volume":"54","author":"BK Sharma","year":"1996","unstructured":"Sharma BK, Jain S, Suri S, Numano F (1996) Diagnostic criteria for Takayasu arteritis. Int J Cardiol 54(Suppl):S141\u2013S147","journal-title":"Int J Cardiol"},{"key":"5743_CR18","doi-asserted-by":"publisher","unstructured":"Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, al-Mayouf S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, Djeddi D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli S, Martini A, Ruperto N, for the Paediatric Rheumatology International Trials Organisation (PRINTO) (2010) EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 69:798\u2013806. https:\/\/doi.org\/10.1136\/ard.2009.116657","DOI":"10.1136\/ard.2009.116657"},{"key":"5743_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.7326\/0003-4819-120-11-199406010-00004","volume":"120","author":"GS Kerr","year":"1994","unstructured":"Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS (1994) Takayasu arteritis. Ann Intern Med 120:919\u2013929","journal-title":"Ann Intern Med"},{"key":"5743_CR20","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/rheumatology\/ket128","volume":"52","author":"R Misra","year":"2013","unstructured":"Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, Jeyaseelan L, Lawrence A, Bacon PA, Indian Rheumatology Vasculitis (IRAVAS) group (2013) Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 52:1795\u20131801. https:\/\/doi.org\/10.1093\/rheumatology\/ket128","journal-title":"Rheumatology (Oxford)"},{"key":"5743_CR21","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"5743_CR22","unstructured":"Newcastle-Ottawa scale. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp [Accessed on 14 July 2020]"},{"key":"5743_CR23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10067-020-05291-1","volume":"40","author":"L Li","year":"2021","unstructured":"Li L, Liu C, Cheng L, Yan S, Chen H, Li Y (2021) Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Clin Rheumatol 40:819\u2013832. https:\/\/doi.org\/10.1007\/s10067-020-05291-1","journal-title":"Clin Rheumatol"},{"key":"5743_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3346\/jkms.2018.33.e92","volume":"33","author":"DP Misra","year":"2018","unstructured":"Misra DP, Agarwal V (2018) Systematic reviews: challenges for their justification, related comprehensive searches, and implications. J Korean Med Sci 33:9. https:\/\/doi.org\/10.3346\/jkms.2018.33.e92","journal-title":"J Korean Med Sci"},{"key":"5743_CR25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H (2018) Quantifying publication bias in meta-analysis. Biometrics 74:785\u2013794. https:\/\/doi.org\/10.1111\/biom.12817","journal-title":"Biometrics"},{"key":"5743_CR26","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2020 (developed by Evidence Prime, Inc.). Available from gradepro.org. [Accessed on 04 September 2020]"},{"key":"5743_CR27","unstructured":"Online calculator for pooling variances. https:\/\/home.ubalt.edu\/ntsbarsh\/business-stat\/otherapplets\/Pooled.htm [Accessed on 04 September 2020]."},{"key":"5743_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","volume":"72","author":"VN Nyaga","year":"2014","unstructured":"Nyaga VN, Arbyn M, Aerts M (2014) Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 72:39. https:\/\/doi.org\/10.1186\/2049-3258-72-39","journal-title":"Arch Public Health"},{"key":"5743_CR29","unstructured":"Practical Meta-analysis effect size calculator. Available at https:\/\/campbellcollaboration.org\/escalc\/html\/EffectSizeCalculator-SMD1.php [Accessed on 04 September 2020]"},{"key":"5743_CR30","first-page":"1081","volume":"18","author":"E Morales","year":"1991","unstructured":"Morales E, Pineda C, Mart\u00ednez-Lav\u00edn M (1991) Takayasu's arteritis in children. J Rheumatol 18:1081\u20131084","journal-title":"J Rheumatol"},{"key":"5743_CR31","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00296-015-3272-7","volume":"35","author":"DP Misra","year":"2015","unstructured":"Misra DP, Aggarwal A, Lawrence A, Agarwal V, Misra R (2015) Pediatric-onset Takayasu's arteritis: clinical features and short-term outcome. Rheumatol Int 35:1701\u20131706. https:\/\/doi.org\/10.1007\/s00296-015-3272-7","journal-title":"Rheumatol Int"},{"key":"5743_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/0003-4819-103-1-121","volume":"103","author":"JH Shelhamer","year":"1985","unstructured":"Shelhamer JH, Volkman DJ, Parrillo JE, Lawley TJ, Johnston MR, Fauci AS (1985) Takayasu's arteritis and its therapy. Ann Intern Med 103:121\u2013126. https:\/\/doi.org\/10.7326\/0003-4819-103-1-121","journal-title":"Ann Intern Med"},{"key":"5743_CR33","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/art.1780370420","volume":"37","author":"GS Hoffman","year":"1994","unstructured":"Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS (1994) Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37:578\u2013582. https:\/\/doi.org\/10.1002\/art.1780370420","journal-title":"Arthritis Rheum"},{"key":"5743_CR34","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s004670050526","volume":"12","author":"D Hahn","year":"1998","unstructured":"Hahn D, Thomson PD, Kala U, Beale PG, Levin SE (1998) A review of Takayasu's arteritis in children in Gauteng, South Africa. Pediatr Nephrol 12:668\u2013675. https:\/\/doi.org\/10.1007\/s004670050526","journal-title":"Pediatr Nephrol"},{"key":"5743_CR35","first-page":"1793","volume":"30","author":"AK Valsakumar","year":"2003","unstructured":"Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N (2003) Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 30:1793\u20131798","journal-title":"J Rheumatol"},{"key":"5743_CR36","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1002\/art.20300","volume":"50","author":"GS Hoffman","year":"2004","unstructured":"Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50:2296\u20132304. https:\/\/doi.org\/10.1002\/art.20300","journal-title":"Arthritis Rheum"},{"key":"5743_CR37","first-page":"376","volume":"66","author":"E Baldissera","year":"2007","unstructured":"Baldissera E, Dagna L, Tiraboschi M et al (2007) Anti-TNF alpha agents in Takayasu's arteritis: an Italian experience. Ann Rheum Dis 66:376\u2013376","journal-title":"Ann Rheum Dis"},{"key":"5743_CR38","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.avsg.2007.03.021","volume":"21","author":"S de Franciscis","year":"2007","unstructured":"de Franciscis S, Serra R, Luongo A, Sabino G, Puzziello A (2007) The management of Takayasu's arteritis: personal experience. Ann Vasc Surg 21:754\u2013760. https:\/\/doi.org\/10.1016\/j.avsg.2007.03.021","journal-title":"Ann Vasc Surg"},{"key":"5743_CR39","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s10067-007-0596-z","volume":"26","author":"SK Shinjo","year":"2007","unstructured":"Shinjo SK, Pereira RMR, Tizziani VAP, Radu AS, Levy-Neto M (2007) Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol 26:1871\u20131875. https:\/\/doi.org\/10.1007\/s10067-007-0596-z","journal-title":"Clin Rheumatol"},{"key":"5743_CR40","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1136\/ard.2008.093260","volume":"67","author":"ES Molloy","year":"2008","unstructured":"Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67:1567\u20131569. https:\/\/doi.org\/10.1136\/ard.2008.093260","journal-title":"Ann Rheum Dis"},{"key":"5743_CR41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10067-009-1333-6","volume":"29","author":"R Goel","year":"2010","unstructured":"Goel R, Danda D, Mathew J, Edwin N (2010) Mycophenolate mofetil in Takayasu's arteritis. Clin Rheumatol 29:329\u2013332. https:\/\/doi.org\/10.1007\/s10067-009-1333-6","journal-title":"Clin Rheumatol"},{"key":"5743_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3109\/03009742.2011.633553","volume":"41","author":"AWS De Souza","year":"2012","unstructured":"De Souza AWS, Da Silva MD, MacHado LSG, Oliveira ACD, Pinheiro FAG, Sato EI (2012) Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 41:227\u2013230. https:\/\/doi.org\/10.3109\/03009742.2011.633553","journal-title":"Scand J Rheumatol"},{"key":"5743_CR43","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/rheumatology\/ker380","volume":"51","author":"A Mekinian","year":"2012","unstructured":"Mekinian A, N\u00e9el A, Sibilia J et al (2012) Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) 51:882\u2013886. https:\/\/doi.org\/10.1093\/rheumatology\/ker380","journal-title":"Rheumatology (Oxford)"},{"key":"5743_CR44","first-page":"922","volume":"30","author":"L Quartuccio","year":"2012","unstructured":"Quartuccio L, Schiavon F, Zuliani F, Carraro V, Catarsi E, Tavoni AG, Bombardieri S, Punzi L, de Vita S (2012) Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 30:922\u2013928","journal-title":"Clin Exp Rheumatol"},{"key":"5743_CR45","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/acr.21636","volume":"64","author":"J Schmidt","year":"2012","unstructured":"Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ (2012) Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term followup. Arthritis Care Res 64:1079\u20131083. https:\/\/doi.org\/10.1002\/acr.21636","journal-title":"Arthritis Care Res"},{"key":"5743_CR46","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.autrev.2013.06.019","volume":"12","author":"N Abisror","year":"2013","unstructured":"Abisror N, Mekinian A, Lavigne C, Vandenhende MA, Soussan M, Fain O (2013) Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev 12:1143\u20131149. https:\/\/doi.org\/10.1016\/j.autrev.2013.06.019","journal-title":"Autoimmun Rev"},{"key":"5743_CR47","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/1756-185x.12220","volume":"16","author":"R Goel","year":"2013","unstructured":"Goel R, Danda D, Kumar S, Joseph G (2013) Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis. Int J Rheum Dis 16:754\u2013761. https:\/\/doi.org\/10.1111\/1756-185x.12220","journal-title":"Int J Rheum Dis"},{"key":"5743_CR48","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/annrheumdis-2012-eular.2174","volume":"71","author":"E Tombetti","year":"2013","unstructured":"Tombetti E, Baldissera E, Franchini S, Motta F, Aiello P, Cavalli G, Sabbadini MG (2013) Efficacy of anti-TNF therapy in 15 patients with refractory Takayasu's arteritis: long term unicentric follow-up. Ann Rheum Dis 71:226. https:\/\/doi.org\/10.1136\/annrheumdis-2012-eular.2174","journal-title":"Ann Rheum Dis"},{"key":"5743_CR49","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3899\/jrheum.130536","volume":"40","author":"E Tombetti","year":"2013","unstructured":"Tombetti E, Franchini S, Papa M, Sabbadini MG, Baldissera E (2013) Treatment of refractory takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol 40:2047\u20132051. https:\/\/doi.org\/10.3899\/jrheum.130536","journal-title":"J Rheumatol"},{"key":"5743_CR50","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/rhu.0000000000000098","volume":"20","author":"CA Canas","year":"2014","unstructured":"Canas CA, Canas F, Izquierdo JH et al (2014) Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J Clin Rheumatol 20:125\u2013129. https:\/\/doi.org\/10.1097\/rhu.0000000000000098","journal-title":"J Clin Rheumatol"},{"key":"5743_CR51","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1136\/annrheumdis-2014-eular.2984","volume":"32","author":"J Loricera","year":"2014","unstructured":"Loricera J, Blanco R, Castaneda S et al (2014) Tocilizumab in refractory aortitis: a study on 16 patients and literature review. Clin Exp Rheumatol 32:S79\u2013S89. https:\/\/doi.org\/10.1136\/annrheumdis-2014-eular.2984","journal-title":"Clin Exp Rheumatol"},{"key":"5743_CR52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4103\/0976-500X.136101","volume":"5","author":"R Serra","year":"2014","unstructured":"Serra R, Grande R, Buffone G, Scarcello E, Tripodi F, Rende P, Gallelli L, de Franciscis S (2014) Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis. J Pharmacol Pharmacother 5:193\u2013196. https:\/\/doi.org\/10.4103\/0976-500X.136101","journal-title":"J Pharmacol Pharmacother"},{"key":"5743_CR53","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/RHU.0000000000000106","volume":"20","author":"S Stern","year":"2014","unstructured":"Stern S, Clemente G, Reiff A, Ramos MPR, Marzan KA, Terreri MT (2014) Treatment of pediatric Takayasu arteritis with infliximab and cyclophosphamide: experience from an American-Brazilian cohort study. J Clin Rheumatol 20:183\u2013188. https:\/\/doi.org\/10.1097\/RHU.0000000000000106","journal-title":"J Clin Rheumatol"},{"key":"5743_CR54","first-page":"S11","volume":"32","author":"T Youngstein","year":"2014","unstructured":"Youngstein T, Peters JE, Hamdulay SS, Mewar D, Price-Forbes A, Lloyd M, Jeffery R, Kinderlerer AR, Mason JC (2014) Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-alpha and IL-6 receptor targeted therapies in refractory Takayasu arteritis. Clin Exp Rheumatol 32:S11\u2013S18","journal-title":"Clin Exp Rheumatol"},{"key":"5743_CR55","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/circulationaha.114.014321","volume":"132","author":"A Mekinian","year":"2015","unstructured":"Mekinian A, Comarmond C, Resche-Rigon M, Mirault T, Kahn JE, Lambert M, Sibilia J, N\u00e9el A, Cohen P, Hie M, Berthier S, Marie I, Lavigne C, Anne Vandenhende M, Muller G, Amoura Z, Devilliers H, Abad S, Hamidou M, Guillevin L, Dhote R, Godeau B, Messas E, Cacoub P, Fain O, Saadoun D, French Takayasu Network (2015) Efficacy of biological-targeted treatments in Takayasu arteritis multicenter, retrospective study of 49 patients. Circulation 132:1693\u20131700. https:\/\/doi.org\/10.1161\/circulationaha.114.014321","journal-title":"Circulation"},{"key":"5743_CR56","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/annrheumdis-2015-eular.6048","volume":"74","author":"P Novikov","year":"2015","unstructured":"Novikov P, Smitienko I, Elonakov A, Koilubaeva G, Moiseev S (2015) Safety and efficacy of short-term treatment with tocilizumab in patients with refractory Takayasu arteritis. Ann Rheum Dis 74:302. https:\/\/doi.org\/10.1136\/annrheumdis-2015-eular.6048","journal-title":"Ann Rheum Dis"},{"key":"5743_CR57","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.rbr.2015.09.007","volume":"56","author":"AWS de Souza","year":"2016","unstructured":"de Souza AWS, Agustinelli RD, Almeida HD et al (2016) Leflunomide in Takayasu arteritis\u2014a long term observational study. Rev Bras Reumatol Engl Ed 56:371\u2013375. https:\/\/doi.org\/10.1016\/j.rbr.2015.09.007","journal-title":"Rev Bras Reumatol Engl Ed"},{"key":"5743_CR58","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/srep38687","volume":"6","author":"J Li","year":"2016","unstructured":"Li J, Yang YJ, Zhao JL, Li MT, Tian XP, Zeng XF (2016) The efficacy of Mycophenolate mofetil for the treatment of Chinese Takayasu's arteritis. Sci Rep 6:7. https:\/\/doi.org\/10.1038\/srep38687","journal-title":"Sci Rep"},{"key":"5743_CR59","first-page":"S44","volume":"34","author":"J Loricera","year":"2016","unstructured":"Loricera J, Blanco R, Hern\u00e1ndez JL, Casta\u00f1eda S, Humbr\u00eda A, Ortego N, Bravo B, Freire M, Melchor S, M\u00ednguez M, Salvatierra J, Gonz\u00e1lez-Vela C, Calvo-R\u00edo V, Santos-G\u00f3mez M, Pina T, Gonz\u00e1lez-Gay MA (2016) Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol 34:S44\u2013S53","journal-title":"Clin Exp Rheumatol"},{"key":"5743_CR60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13075-017-1452-4","volume":"19","author":"FA Aeschlimann","year":"2017","unstructured":"Aeschlimann FA, Eng SWM, Sheikh S, Laxer RM, Hebert D, Noone D, Twilt M, Pagnoux C, Benseler SM, Yeung RSM (2017) Childhood Takayasu arteritis: disease course and response to therapy. Arthritis Res Ther 19:10. https:\/\/doi.org\/10.1186\/s13075-017-1452-4","journal-title":"Arthritis Res Ther"},{"key":"5743_CR61","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13075-017-1316-y","volume":"19","author":"B Gudbrandsson","year":"2017","unstructured":"Gudbrandsson B, Molberg \u00d8, Palm \u00d8 (2017) TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study. Arthritis Res Ther 19:99\u201399. https:\/\/doi.org\/10.1186\/s13075-017-1316-y","journal-title":"Arthritis Res Ther"},{"key":"5743_CR62","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/annrheumdis-2017-eular.1793","volume":"76","author":"JF Kleinmann","year":"2017","unstructured":"Kleinmann JF, Arnaud L, Sauleau E et al (2017) Efficacy and safety of infliximab originator in patients with Takayasu arteritis within the RTU (temporary recommendation of use) in France. Ann Rheum Dis 76:611\u2013612. https:\/\/doi.org\/10.1136\/annrheumdis-2017-eular.1793","journal-title":"Ann Rheum Dis"},{"key":"5743_CR63","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40037","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear CA, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA, for the Vasculitis Clinical Research Consortium, Hajj-Ali R, Tuthill K, Gartner K, Madden L, Rice B, Matteson EL, Kermani T, Jaquith J, Amudala N, Clark-Cotton M, Messier S, Farquharson J, Jagadeesh S, McBride D, Venuturupalli S, Wallace D, Phan R, Verde N, Salinas D, Godina J, Davids M, Udeh U, Sejismundo L, Harris J (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheum 69:846\u2013853. https:\/\/doi.org\/10.1002\/art.40037","journal-title":"Arthritis Rheum"},{"key":"5743_CR64","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jjcc.2016.07.009","volume":"69","author":"H Ohigashi","year":"2017","unstructured":"Ohigashi H, Tamura N, Ebana Y, Harigai M, Maejima Y, Ashikaga T, Isobe M (2017) Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment. J Cardiol 69:774\u2013778. https:\/\/doi.org\/10.1016\/j.jjcc.2016.07.009","journal-title":"J Cardiol"},{"key":"5743_CR65","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s12026-017-8917-z","volume":"65","author":"N Shao","year":"2017","unstructured":"Shao N, Jia H, Li Y, Li J (2017) Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-\u03b1: a randomized placebo-controlled double-blind clinical trial. Immunol Res 65:969\u2013974. https:\/\/doi.org\/10.1007\/s12026-017-8917-z","journal-title":"Immunol Res"},{"key":"5743_CR66","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.imbio.2016.10.008","volume":"222","author":"GX Shi","year":"2017","unstructured":"Shi GX, Hua MH, Xu QW, Ren TL (2017) Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: a randomized double-blind and placebo-controlled trial. Immunobiology 222:164\u2013168. https:\/\/doi.org\/10.1016\/j.imbio.2016.10.008","journal-title":"Immunobiology"},{"key":"5743_CR67","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00296-017-3847-6","volume":"37","author":"Y Sun","year":"2017","unstructured":"Sun Y, Ma L, Ma L, Kong X, Chen H, Lv P, Lin J, Liu H, Yan Y, Ji Z, Yang C, Dai S, Wan W, Zou Y, Jin X, Jiang L (2017) Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu\u2019s arteritis. Rheumatol Int 37:2019\u20132026. https:\/\/doi.org\/10.1007\/s00296-017-3847-6","journal-title":"Rheumatol Int"},{"key":"5743_CR68","first-page":"171","volume":"35","author":"J Zhou","year":"2017","unstructured":"Zhou J, Chen Z, Li J et al (2017) The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis. Clin Exp Rheumatol 35:171\u2013175","journal-title":"Clin Exp Rheumatol"},{"key":"5743_CR69","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ijcard.2017.12.066","volume":"266","author":"XF Kong","year":"2018","unstructured":"Kong XF, Zhang XJ, Lv P, Cui X, Ma L, Chen H, Liu H, Lin J, Jiang L (2018) Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide. Int J Cardiol 266:222\u2013228. https:\/\/doi.org\/10.1016\/j.ijcard.2017.12.066","journal-title":"Int J Cardiol"},{"key":"5743_CR70","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2018.04.002","volume":"91","author":"A Mekinian","year":"2018","unstructured":"Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, Constans J, Alric L, Jego P, Busato F, Cabon M, Dhote R, Estibaliz L, Kon\u00e9-Paut I, Landron C, Lavigne C, Lioger B, Michaud M, Ruivard M, Sacre K, Gottenberg JE, Gaches F, Goulenok T, Salvarani C, Cacoub P, Fain O, Saadoun D, French Takayasu network (2018) Efficacy of tocilizumab in Takayasu arteritis: multicenter retrospective study of 46 patients. J Autoimmun 91:55\u201360. https:\/\/doi.org\/10.1016\/j.jaut.2018.04.002","journal-title":"J Autoimmun"},{"key":"5743_CR71","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/rheumatology\/kex493","volume":"57","author":"D Nakagomi","year":"2018","unstructured":"Nakagomi D, Kronbichler A, Witte T, Mohammad AJ, Jayne DRW (2018) Comment on: Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford) 57:1309\u20131310. https:\/\/doi.org\/10.1093\/rheumatology\/kex493","journal-title":"Rheumatology (Oxford)"},{"key":"5743_CR72","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","volume":"77","author":"Y Nakaoka","year":"2018","unstructured":"Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77:348\u2013354. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211878","journal-title":"Ann Rheum Dis"},{"key":"5743_CR73","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1093\/rheumatology\/key197","volume":"57","author":"PI Novikov","year":"2018","unstructured":"Novikov PI, Smitienko IO, Sokolova MV, Alibaz-Oner F, Kaymaz-Tahra S, Direskeneli H, Moiseev SV (2018) Certolizumab pegol in the treatment of Takayasu arteritis. Rheumatology (Oxford) 57:2101\u20132105. https:\/\/doi.org\/10.1093\/rheumatology\/key197","journal-title":"Rheumatology (Oxford)"},{"key":"5743_CR74","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s00296-018-4159-1","volume":"38","author":"EH Park","year":"2018","unstructured":"Park EH, Lee EY, Lee YJ, Ha YJ, Yoo WH, Choi BY, Paeng JC, Suh HY, Song YW (2018) Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study. Rheumatol Int 38:2233\u20132242. https:\/\/doi.org\/10.1007\/s00296-018-4159-1","journal-title":"Rheumatol Int"},{"key":"5743_CR75","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/rheumatology\/kex249","volume":"57","author":"G Pazzola","year":"2018","unstructured":"Pazzola G, Muratore F, Pipitone N, Crescentini F, Cacoub P, Boiardi L, Spaggiari L, Comarmond C, Croci S, Saadoun D, Salvarani C (2018) Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford) 57:1151\u20131155. https:\/\/doi.org\/10.1093\/rheumatology\/kex249","journal-title":"Rheumatology (Oxford)"},{"key":"5743_CR76","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1136\/annrheumdis-2019-eular.4429","volume":"78","author":"M Kato","year":"2019","unstructured":"Kato M, Okuda H, Kameda T et al (2019) The usefulness of 18F-fluorodeoxyglucose positron emission tomography CT (18F-FDG PET\/CT) as an imaging biomarker in Takayasu arteritis treated with tocilizumab. Ann Rheum Dis 78:1758\u20131759. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.4429","journal-title":"Ann Rheum Dis"},{"key":"5743_CR77","first-page":"158","volume":"58","author":"K Shah","year":"2019","unstructured":"Shah K, Mason JC (2019) Real life experience of tocilizumab for Takayasu arteritis. Rheumatology (Oxford) 58:158\u2013158","journal-title":"Rheumatology (Oxford)"},{"key":"5743_CR78","doi-asserted-by":"crossref","unstructured":"Wang T, Liao H (2019) Comparison of efficacy and safety between tocilizumab and cyclophosphamide in treating patients with Takayasu's arteritis. Rheumatology (Oxford) 58:1","DOI":"10.1093\/rheumatology\/kez063.086"},{"key":"5743_CR79","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3899\/jrheum.181222","volume":"47","author":"S Banerjee","year":"2020","unstructured":"Banerjee S, Quinn KA, Gribbons KB, Rosenblum JS, Civelek AC, Novakovich E, Merkel PA, Ahlman MA, Grayson PC (2020) Effect of treatment on imaging, clinical, and serologic assessments of disease activity in large-vessel vasculitis. J Rheumatol 47:99\u2013107. https:\/\/doi.org\/10.3899\/jrheum.181222","journal-title":"J Rheumatol"},{"key":"5743_CR80","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.semarthrit.2020.01.005","volume":"50","author":"C Campochiaro","year":"2020","unstructured":"Campochiaro C, Tomelleri A, Sartorelli S, Cavalli G, de Luca G, Baldissera E, Dagna L (2020) Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. Semin Arthritis Rheum 50:509\u2013514. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.01.005","journal-title":"Semin Arthritis Rheum"},{"key":"5743_CR81","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1136\/annrheumdis-2020-eular.3250","volume":"79","author":"C Campochiaro","year":"2020","unstructured":"Campochiaro C, Tomelleri A, Sartorelli S, de Luca G, Sembenini C, Cavalli G, Mapelli P, Picchio M, Papa M, Baldissera E, Dagna L (2020) Efficacy and safety of infliximab-biosimilar in Takayasu arteritis (TAKASIM): a monocentric, observational, prospective, open-label study. Ann Rheum Dis 79:1527. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.3250","journal-title":"Ann Rheum Dis"},{"key":"5743_CR82","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.semarthrit.2019.06.009","volume":"50","author":"X Cui","year":"2020","unstructured":"Cui X, Dai X, Ma L, Yang C, Tan W, Zhang L, Zhang Z, Feng X, Wu R, Zou Y, Zhou Z, Lu Y, Wang Y, Wu M, Li S, Wang L, Lin H, Dong Z, Fu W, Sun X, Wang C, Ding J, Lv P, Lin J, Jiang L, East China Takayasu Arteritis (ECTA) Collaboration Group (2020) Efficacy and safety of leflunomide treatment in Takayasu arteritis: case series from the East China cohort. Semin Arthritis Rheum 50:59\u201365. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.06.009","journal-title":"Semin Arthritis Rheum"},{"key":"5743_CR83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2040622320922019","volume":"11","author":"X Dai","year":"2020","unstructured":"Dai X, Cui X, Sun Y, Ma L, Jiang L (2020) Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu\u2019s arteritis: an observational study. Ther Adv Chronic Dis 11:11. https:\/\/doi.org\/10.1177\/2040622320922019","journal-title":"Ther Adv Chronic Dis"},{"key":"5743_CR84","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/14397595.2020.1800560","volume":"31","author":"Y Gon","year":"2020","unstructured":"Gon Y, Yoshifuji H, Nakajima T, Murakami K, Nakashima R, Ohmura K, Mimori T, Terao C (2020) Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab. Mod Rheumatol 31:678\u2013683. https:\/\/doi.org\/10.1080\/14397595.2020.1800560","journal-title":"Mod Rheumatol"},{"key":"5743_CR85","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3906\/sag-1906-39","volume":"50","author":"L Kili\u00e7","year":"2020","unstructured":"Kili\u00e7 L, Karada\u011f \u00d6, Erden A et al (2020) Anti-interleukin-6 (Tocilizumab) therapy in takayasu\u2019s arteritis: a real life experience. Turk J Med Sci 50:31\u201336. https:\/\/doi.org\/10.3906\/sag-1906-39","journal-title":"Turk J Med Sci"},{"key":"5743_CR86","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1093\/rheumatology\/keaa281","volume":"59","author":"J Li","year":"2020","unstructured":"Li J, Li M, Tian X, Zeng X (2020) Tofacitinib in patients with refractory Takayasu's arteritis. Rheumatology (Oxford) 59:e95\u2013e98. https:\/\/doi.org\/10.1093\/rheumatology\/keaa281","journal-title":"Rheumatology (Oxford)"},{"key":"5743_CR87","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13075-020-02311-y","volume":"22","author":"A Mekinian","year":"2020","unstructured":"Mekinian A, Saadoun D, Vicaut E et al (2020) Tocilizumab in treatment-naive patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial. Arthritis Res Ther 22:7. https:\/\/doi.org\/10.1186\/s13075-020-02311-y","journal-title":"Arthritis Res Ther"},{"key":"5743_CR88","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.autrev.2020.102634","volume":"19","author":"P Mertz","year":"2020","unstructured":"Mertz P, Kleinmann JF, Lambert M, Pu\u00e9chal X, Bonnin A, Boulon C, Diot E, Hachulla E, Harid N, Harle JR, Helder G, Kahn JE, Kone-Paut I, Lavigne C, Magy-Bertrand N, Maillard H, Martin T, Maurier F, Poindron V, Schleinitz N, Sibilia J, Arnaud L (2020) Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: results of a multicenter open-label prospective study. Autoimmun Rev 19:4. https:\/\/doi.org\/10.1016\/j.autrev.2020.102634","journal-title":"Autoimmun Rev"},{"key":"5743_CR89","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1093\/rheumatology\/kez630","volume":"59","author":"Y Nakaoka","year":"2020","unstructured":"Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno S, Yoshifuji H, Sakata Y, Kawakami A, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, Okada N, Yamakido S, Takei S, Yokota S, Nishimoto N (2020) Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology (Oxford) 59:2427\u20132434. https:\/\/doi.org\/10.1093\/rheumatology\/kez630","journal-title":"Rheumatology (Oxford)"},{"key":"5743_CR90","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s10067-020-05005-7","volume":"39","author":"L Pan","year":"2020","unstructured":"Pan L, Du J, Liu J et al (2020) Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis. Clin Rheumatol 39:2369\u20132378. https:\/\/doi.org\/10.1007\/s10067-020-05005-7","journal-title":"Clin Rheumatol"},{"key":"5743_CR91","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/annrheumdis-2020-eular.2445","volume":"79","author":"D Prieto-Pena","year":"2020","unstructured":"Prieto-Pena D, Calderon-Goercke M, Bernabeu P et al (2020) Tocilizumab in refractory Takayasu arteritis. open-label national multicenter study of 53 patients of clinical practice. Ann Rheum Dis 79:1074\u20131075. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.2445","journal-title":"Ann Rheum Dis"},{"key":"5743_CR92","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1136\/annrheumdis-2020-eular.5778","volume":"79","author":"C Wang","year":"2020","unstructured":"Wang C, Song H, Yu Z, Quan M (2020) AB1009\u00a0The efficacy of tocilizumab on the treatment of Takayasu arteritis in Chinese children. Ann Rheum Dis 79:1798\u2013171798. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.5778","journal-title":"Ann Rheum Dis"},{"key":"5743_CR93","doi-asserted-by":"publisher","first-page":"204062232097523","DOI":"10.1177\/2040622320975233","volume":"11","author":"C Wu","year":"2020","unstructured":"Wu C, Sun Y, Cui X, Wu S, Ma L, Chen H, Yan Y, Ji Z, Liu Y, Lin J, Lv P, Chen R, Yang P, Jiang L (2020) Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis. Ther Adv Chronic Dis 11:204062232097523. https:\/\/doi.org\/10.1177\/2040622320975233","journal-title":"Ther Adv Chronic Dis"},{"key":"5743_CR94","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1759720x20930114","volume":"12","author":"S Ying","year":"2020","unstructured":"Ying S, Cui XM, Dai XM et al (2020) Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study. Ther Adv Musculoskeletal Dis 12:11. https:\/\/doi.org\/10.1177\/1759720x20930114","journal-title":"Ther Adv Musculoskeletal Dis"},{"key":"5743_CR95","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jjcc.2020.12.011","volume":"77","author":"M Isobe","year":"2021","unstructured":"Isobe M, Maejima Y, Saji M, Tateishi U (2021) Evaluation of tocilizumab for intractable Takayasu arteritis and 18F-fluorodeoxyglucose-positron emission tomography for detecting inflammation under tocilizumab treatment. J Cardiol 77:539\u2013544. https:\/\/doi.org\/10.1016\/j.jjcc.2020.12.011","journal-title":"J Cardiol"},{"key":"5743_CR96","doi-asserted-by":"publisher","unstructured":"Rongyi C, Zongfei J, Jiang L, Sifan W, Lingying M, Ying S, Wenshu Y, Xiaomeng C, Xiufang K, Xiaomin D, Lili M, Yanshan L, Lindi J (2021) Effect of hydroxychloroquine on angiographic progression in routine treatment of Takayasu arteritis. Mod Rheumatol:1\u201317. https:\/\/doi.org\/10.1080\/14397595.2021.1879347","DOI":"10.1080\/14397595.2021.1879347"},{"key":"5743_CR97","doi-asserted-by":"publisher","unstructured":"Wei Y, Zhao C, Liang J, et al. (2021) Factors associated with event-free survival in Chinese patients with Takayasu's arteritis. Clin Rheumatol. doi:https:\/\/doi.org\/10.1007\/s10067-020-05481-x","DOI":"10.1007\/s10067-020-05481-x"},{"key":"5743_CR98","doi-asserted-by":"crossref","unstructured":"Erbasan F, U\u00e7ar \u0130, Aslan B, Yazisiz V, Terzio\u011flu ME (2021) The effects of biological agents on vascular structural lesions in Takayasu's arteritis. Clin Exp Rheumatol","DOI":"10.55563\/clinexprheumatol\/z6drbj"},{"key":"5743_CR99","unstructured":"Mustapha N, Barra L, Carette S, et al. (2020) Efficacy of leflunomide in the treatment of vasculitis. Clin Exp Rheumatol"},{"key":"5743_CR100","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/ard.2008.090068","volume":"68","author":"M Hirao","year":"2009","unstructured":"Hirao M, Hashimoto J, Tsuboi H, Nampei A, Nakahara H, Yoshio N, Mima T, Yoshikawa H, Nishimoto N (2009) Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis 68:654\u2013657. https:\/\/doi.org\/10.1136\/ard.2008.090068","journal-title":"Ann Rheum Dis"},{"key":"5743_CR101","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear CA, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA, for the Vasculitis Clinical Research Consortium, Hajj-Ali R, Tuthill K, Gartner K, Madden L, Matteson EL, Kermani T, Jaquith J, Amudala N, Clark-Cotton M, Messier S, Farquharson J, Jagadeesh S, McBride D, Venuturupalli S, Wallace D, Phan R, Verde N, Salinas D, Godina J, Davids M, Udeh U, Sejismundo L, Harris J (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheum 69:837\u2013845. https:\/\/doi.org\/10.1002\/art.40044","journal-title":"Arthritis Rheum"},{"key":"5743_CR102","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jclinepi.2015.03.017","volume":"68","author":"J IntHout","year":"2015","unstructured":"IntHout J, Ioannidis JPA, Borm GF, Goeman JJ (2015) Small studies are more heterogeneous than large ones: a meta-meta-analysis. J Clin Epidemiol 68:860\u2013869. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.03.017","journal-title":"J Clin Epidemiol"},{"key":"5743_CR103","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nrrheum.2015.116","volume":"11","author":"LHD van Tuyl","year":"2015","unstructured":"van Tuyl LHD, Boers M (2015) Patient-reported outcomes in core domain sets for rheumatic diseases. Nat Rev Rheumatol 11:705\u2013712. https:\/\/doi.org\/10.1038\/nrrheum.2015.116","journal-title":"Nat Rev Rheumatol"},{"key":"5743_CR104","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.autrev.2011.08.001","volume":"11","author":"L Arnaud","year":"2011","unstructured":"Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z (2011) Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev 11:61\u201367. https:\/\/doi.org\/10.1016\/j.autrev.2011.08.001","journal-title":"Autoimmun Rev"},{"key":"5743_CR105","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s10067-020-05045-z","volume":"39","author":"D Castillo-Mart\u00ednez","year":"2020","unstructured":"Castillo-Mart\u00ednez D, Amezcua-Castillo LM, Granados J, Pineda C, Amezcua-Guerra LM (2020) Is Takayasu arteritis the result of a Mycobacterium tuberculosis infection? The use of TNF inhibitors may be the proof-of-concept to demonstrate that this association is epiphenomenal. Clin Rheumatol 39:2003\u20132009. https:\/\/doi.org\/10.1007\/s10067-020-05045-z","journal-title":"Clin Rheumatol"},{"key":"5743_CR106","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/art.39037","volume":"67","author":"D Saadoun","year":"2015","unstructured":"Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, Terrier B, Geri G, Rosenzwajg M, Klatzmann D, Fourret P, Cluzel P, Chiche L, Gaudric J, Koskas F, Cacoub P (2015) Th1 and Th17 cytokines drive inflammation in takayasu arteritis. Arthritis Rheum 67:1353\u20131360. https:\/\/doi.org\/10.1002\/art.39037","journal-title":"Arthritis Rheum"},{"key":"5743_CR107","doi-asserted-by":"publisher","unstructured":"Misra DP, Chaurasia S, Misra R (2016) Increased circulating Th17 cells, serum IL-17A, and IL-23 in Takayasu arteritis. Autoimmun Dis 8. https:\/\/doi.org\/10.1155\/2016\/7841718","DOI":"10.1155\/2016\/7841718"},{"key":"5743_CR108","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.injr.2016.04.001","volume":"11","author":"DP Misra","year":"2016","unstructured":"Misra DP, Negi VS (2016) Takayasu's arteritis. Indian J Rheumatol 11:73\u201377. https:\/\/doi.org\/10.1016\/j.injr.2016.04.001","journal-title":"Indian J Rheumatol"},{"key":"5743_CR109","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41584-020-0454-9","volume":"16","author":"E Gracey","year":"2020","unstructured":"Gracey E, Vereecke L, McGovern D, Fr\u00f6hling M, Schett G, Danese S, de Vos M, van den Bosch F, Elewaut D (2020) Revisiting the gut\u2013joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol 16:415\u2013433. https:\/\/doi.org\/10.1038\/s41584-020-0454-9","journal-title":"Nat Rev Rheumatol"},{"key":"5743_CR110","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","volume":"58","author":"EH Choy","year":"2019","unstructured":"Choy EH (2019) Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford) 58:953\u2013962. https:\/\/doi.org\/10.1093\/rheumatology\/key339","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05743-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:44:23Z","timestamp":1744152263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05743-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":110,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["5743"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05743-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}